Hsp90-targeted miRNA-liposomal formulation for systemic antitumor effect

Biomaterials

Volumn 34, Issue 28, 2013, Pages 6804-6817

  Pore, Subrata Kumar ^a   Choudhary, Ashwani ^b   Rathore, Bhowmira ^a   Ganguly, Anirban ^a   Sujitha, Pombala ^a   Ganesh Kumar, C ^a   Agawane, Sachin Bharat ^a,d   Kumar, Jerald Mahesh ^c   Scaria, Vinod ^b   Pillai, Beena ^b   Banerjee, Rajkumar ^a  

^a INDIAN INSTITUTE OF CHEMICAL TECHNOLOGY   (India)

^b CSIR INSTITUTE OF GENOMICS AND INTEGRATIVE BIOLOGY   (India)

^c CENTRE FOR CELLULAR AND MOLECULAR BIOLOGY   (India)

^d NATIONAL CHEMICAL LABORATORY   (India)

Author keywords

Akt; Cancer; Glucocorticoid receptor; Hsp90; Liposome; P53

Indexed keywords

AKT; CANCER; GLUCOCORTICOID RECEPTOR; HSP90; P53;

CELL DEATH; DISEASES; DNA; HORMONES; LIPOSOMES; RNA; TRANSCRIPTION FACTORS;

TUMORS;

ANTINEOPLASTIC AGENT; ARTIFICIAL MICRORNA AGAINST HEAT SHOCK PROTEIN 90; CASPASE 3; GLUCOCORTICOID RECEPTOR; LIPOPLEX; LIPOSOME; PROTEIN KINASE B; PROTEIN P53; UNCLASSIFIED DRUG; VASCULOTROPIN RECEPTOR 2;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER SIZE; CELL VIABILITY; CONTROLLED STUDY; DOWN REGULATION; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG FORMULATION; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; NONVIRAL GENE THERAPY; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; UPREGULATION;

ANIMALS; ANTINEOPLASTIC AGENTS; BLOTTING, WESTERN; CELL LINE, TUMOR; COS CELLS; FEMALE; HSP90 HEAT-SHOCK PROTEINS; HUMANS; LIPOSOMES; MICE; MICE, INBRED C57BL; MICE, NUDE; MICRORNAS; NIH 3T3 CELLS; POLYMERASE CHAIN REACTION; RECEPTORS, GLUCOCORTICOID;

MUS;

EID: 84879462491     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2013.05.054     Document Type: Article

References (38)

1. Hendrick J.P., Hartl F.U. Molecular chaperone functions of heat shock proteins. Annu Rev Biochem 1993, 62:349-384.
2. Fu Hartl, Hayer-Hartl M. Molecular chaperones in the cytosol: from nascent chain to folded protein. Science 2002, 295:1852-1858.
3. Zhang H., Burrows F. Targeting multiple signal transduction pathways through inhibition of Hsp90. JMol Med 2004, 82:488-499.
4. Whitesell L., Lindquist S.L. HSP90 and chaperoning of cancer. Nat Rev Cancer 2005, 5:761-772.
5. For detailed list . http://www.picard.ch/downloads/Hsp90interactors.pdf.
6. Gimenez Ortiz A., Montalar Salcedo J. Heat shock proteins as targets in oncology. Clin Transl Oncol 2010, 12:166-173.
7. Hanahan D., Weinberg R.A. Hallmarks of cancer. Cell 2000, 100:57-70.
8. Hanahan D., Weinberg R.A. Hallmarks of cancer: the next generation. Cell 2011, 144:646-674.
9. Ciocca D.R., Calderwood S.K. Heat shock proteins in cancer: diagnostic, prognostic, predictive, and treatment implications. Cell Stress Chaperones 2005, 10:86-103.
10. Gress T.M., Müller-Pillasch F., Weber C., Lerch M.M., Friess H., Büchler M., et al. Differential expression of heat shock proteins in pancreatic carcinoma. Cancer Res 1994, 54:547-551.
11. Ferrarini M., Heltai S., Zocchi M.R., Rugarli C. Unusual expression and localization of heat-shock proteins in human tumor cells. Int J Cancer 1992, 51:613-619.
12. Cardillo M.R., Sale P., Di Silverio F. Heat shock protein-90, IL-6 and IL-10 in bladder cancer. Anticancer Res 2000, 20:4579-4583.
13. Neckers L. Hsp90 inhibitors as novel cancer chemotherapeutic agents. Trends Mol Med 2002, 8:S55-S61.
14. Sharp S., Workman P. Inhibitors of the molecular chaperone Hsp90: current status. Adv Cancer Res 2006, 95:323-348.
15. Gyurkocza B., Plescia J., Raskett C.M., Garlick D.S., Lowry P.A., Carter B.Z., et al. Antileukemic activity of shepherdin and molecular diversity of hsp90 inhibitors. JNatl Cancer Inst 2006, 98:1068-1077.
16. Neckers L., Neckers K. Heat-shock protein 90 inhibitors as novel cancer chemotherapeutics - an update. Expert Opin Emerg Drugs 2005, 10:137-149.
17. Heath E.I., Gaskins M., Pitot H.C., Pili R., Tan W., Marschke R., et al. Aphase II trial of 17-allylamino-17-demethoxygeldanamycin in patients with hormone-refractory metastatic prostate cancer. Clin Prostate Cancer 2005, 4:138-141.
18. Oh S.H., Woo J.K., Yazici Y.D., Myers J.N., Kim W.Y., Jin Q., et al. Structural basis for depletion of heat shock protein 90 client proteins by deguelin. JNatl Cancer Inst 2007, 99:949-961.
19. Woo J.K., Choi D.S., Tran H.T., Gilbert B.E., Hong W.K., Lee H.Y. Liposomal encapsulation of deguelin: evidence for enhanced antitumor activity in tobacco carcinogen-induced and oncogenic K-ras-induced lung tumorigenesis. Cancer Prev Res (Phila) 2009, 2:361-369.
20. Song J., Shi F., Zhang Z., Zhu F., Xue J., Tan X., et al. Formulation and evaluation of celastrol-loaded liposomes. Molecules 2011, 16:7880-7892.
21. Slingerland M., Guchelaar H.J., Gelderblom H. Liposomal drug formulations in cancer therapy: 15 years along the road. Drug Discov Today 2012, 17:160-166.
22. Karmali P.P., Chaudhuri A. Cationic liposomes as non-viral carriers of gene medicines: resolved issues, open questions, and future promises. Med Res Rev 2007, 27:696-722.
23. Ashwell J.D., Lu F.W., Vacchio M.S. Glucocorticoids in T cell development and function. Annu Rev Immunol 2000, 18:309-345.
24. Yudt M.R., Cidlowski J.A. The glucocorticoid receptor: coding a diversity of proteins and responses through a single gene. Mol Endocrinol 2002, 16:1719-1726.
25. Bresnick E.H., Dalman F.C., Sanchez E.R., Pratt W.B. Evidence that the 90-kDa heat shock protein is necessary for the steroid binding conformation of the L cell glucocorticoid receptor. JBiol Chem 1989, 264:4992-4997.
26. Bledsoe R.K., Montana V.G., Stanley T.B., Delves C.J., Apolito C.J., McKee D.D., et al. Crystal structure of the glucocorticoid receptor ligand binding domain reveals a novel mode of receptor dimerization and coactivator recognition. Cell 2002, 110:93-105.
27. Mukherjee A., Narayan K.P., Pal K., Kumar J.M., Rangaraj N., Kalivendi S.V., et al. Selective cancer targeting via aberrant behavior of cancer cell-associated glucocorticoid receptor. Mol Ther 2009, 17:623-631.
28. Bartel D.P. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004, 116:281-297.
29. Meister G., Landthaler M., Peters L., Chen P.Y., Urlaub H., Luhrmann R., et al. Identification of novel argonaute-associated proteins. Curr Biol 2005, 15:2149-2155.
30. Gregory R.I., Chendrimada T.P., Cooch N., Shiekhattar R. Human RISC couples microRNA biogenesis and posttranscriptional gene silencing. Cell 2005, 123:631-640.
31. MacRae I.J., Ma E., Zhou M., Robinson C.V., Doudna J.A. Invitro reconstitution of the human RISC-loading complex. Proc Natl Acad Sci U S A 2008, 105:512-517.
32. Pratt A.J., MacRae I.J. The RNA-induced silencing complex: a versatile gene-silencing machine. JBiol Chem 2009, 284:17897-17901.
33. Carmell M.A., Xuan Z., Zhang M.Q., Hannon G.J. The Argonaute family: tentacles that reach into RNAi, developmental control, stem cell maintenance, and tumorigenesis. Genes Dev 2002, 16:2733-2742.
34. Birmingham A., Anderson E.M., Reynolds A., Ilsley-Tyree D., Leake D., Fedorov Y., et al. 3' UTR seed matches, but not overall identity, are associated with RNAi off-targets. Nat Methods 2006, 3:199-204.
35. Fedorov Y., Anderson E.M., Birmingham A., Reynolds A., Karpilow J., Robinson K., et al. Off-target effects by siRNA can induce toxic phenotype. RNA 2006, 12:1188-1190.
36. Pfaffl M.W. Anew mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res 2001, 29:e45.
37. Lin K., Rockliffe N., Johnson G.G., Sherrington P.D., Pettitt A.R. Hsp90 inhibition has opposing effects on wild-type and mutant p53 and induces p21 expression and cytotoxicity irrespective of p53/ATM status in chronic lymphocytic leukaemia cells. Oncogene 2008, 27:2445-2455.
38. Riesterer O., Zingg D., Hummerjohann J., Bodis S., Pruschy M. Degradation of PKB/Akt protein by inhibition of the VEGF receptor/mTOR pathway in endothelial cells. Oncogene 2004, 23:4624-4635.